Recommendations and discussion points on immunogenicity, biomarkers, automation/technology and protein–MS from the 2021 European Bioanalysis Forum Focus Workshops

Author:

Timmerman Philip1,Barfield Matthew2,Cowan Kyra3,Golob Michaela4,Goodman Joanne5,Kunz Ulrich6,Laurén Anna7,Love Iain8,Nelson Robert9,Staack Roland F10,Stanta Johannes11,van de Merbel Nico12,Wilson Amanda13

Affiliation:

1. European Bioanalysis Forum, 1000, Brussels, Belgium

2. Roche Pharma Research & Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F Hoffmann-La Roche Ltd, 4070, Basel, Switzerland

3. Merck KGaA, New Biological Entities Drug Metabolism & Pharmacokinetics, 64293, Darmstadt, Germany

4. Nuvisan GmbH, Bioanalysis, 89231, Neu-Ulm, Germany

5. Integrated Bioanalysis, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, CB21 6GH, UK

6. Boehringer Ingelheim Pharma GmbH & Co. KG, Translational Medicine & Clinical Pharmacology, 88400, Biberach ad Riss, Germany

7. Non-clinical & Clinical Assay Sciences, Global Discovery & Development Sciences, Global Drug Discovery, Novo Nordisk A/S, DK-2760, Måløv, Denmark

8. Charles River Laboratories, Department of Chromatographic Bioanalysis, EH33 2NE, Edinburgh, UK

9. Labcorp Drug Development, Scientific Affairs, 1217, Meyrin, Switzerland

10. Roche Pharma Research & Early Development, Pharmaceutical Sciences, Roche Innovation Center Munich, Roche Diagnostics GmbH, 82377, Penzberg, Germany

11. Freeline Therapeutics, Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, SG1 2FX, UK

12. Icon, Bioanalytical Laboratory, 9407, TK, Assen, The Netherlands

13. Integrated Bioanalysis, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, CB22 3AT, UK

Abstract

During the first half of 2021, and due to the SARS-CoV-2 pandemic preventing in-person meetings, the European Bioanalysis Forum organized four workshops as live interactive online meetings. The themes discussed at the workshops were carefully selected to match the cyberspace dynamics of the meeting format. The first workshop was a training day on challenges related to immunogenicity. The second one focused on biomarkers and continued the important discussion on integrating the principles of Context of Use (CoU) in biomarker research. The third workshop was dedicated to technology, that is, cutting-edge development in cell-based and ligand-binding assays and automation strategies. The fourth was on progress and the continued scientific and regulatory challenges related to peptide and protein analysis with MS. In all four workshops, the European Bioanalysis Forum included a mixture of scientific and regulatory themes, while reminding the audience of important strategic aspects and our responsibility toward the patient.

Publisher

Future Science Ltd

Subject

Medical Laboratory Technology,Clinical Biochemistry,General Pharmacology, Toxicology and Pharmaceutics,General Medicine,Analytical Chemistry

Reference28 articles.

1. Presentations from the Focus Workshop: biomarkers in Pharma R&D – a roadmap from context of use to using the data. https://e-b-f.eu/fw202001-slides/

2. Presentations from the 6th Young Scientist Symposium. https://e-b-f.eu/yss2020-slides/

3. Presentations from the 13th EBF Open Symposium. https://e-b-f.eu/bcn2020-slides/

4. Zoom. https://zoom.us

5. EBF recommendation on practical management of critical reagents for antidrug antibody ligand-binding assays

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3